Comparison of three commercially available assays for HCV RNA using the international unit standard: Implications for management of patients with chronic hepatitis C virus infection in clinical practice

American Journal of Gastroenterology

Volumn 98, Issue 5, 2003, Pages 1159-1166

  Shiffman, Mitchell L ^a   Ferreira Gonzalez, Andrea ^b   Reddy, K Rajender ^b   Sterling, Richard K ^b   Luketic, Velimir A ^b   Stravitz, R Todd ^b   Sanyal, Arun J ^b   Garrett, Carleton T ^b   De Medina, Maria ^b   Schiff, Eugene R ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; ASSAY; CLINICAL PRACTICE; COMPARATIVE STUDY; EVALUATION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERNATIONAL STANDARD UNIT; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE; VIROLOGY; VIRUS LOAD;

EID: 0038408809     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07449.x     Document Type: Article

References (35)

1. De Medina M, Schiff ER. Hepatitis C: Diagnostic assays. Semin Liver Dis 1995;15:33-40.
2. Morishima C, Gretch DR. Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy. Clin Liver Dis 1999;3:717-40.
3. Carithers RL Jr, Marquardt A, Gretch DR. Diagnostic testing for hepatitis C. Semin Liver Dis 2000;20:159-71.
4. Lindsay KL. Therapy of hepatitis C: Overview. Hepatology 1997;26(suppl 1):71-7S.
5. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19(suppl 1):57-65.
6. Davis GL, Lau Y. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(suppl 1):12S-27S.
7. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
8. Reichard O, Norkrans G, Fryden A, et al. Comparison of 3 quantitative HCV RNA assays - accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Scand J Infect Dis 1998;30:441-6.
9. Orito E, Mizokami M, Suzuki K, et al. Loss of serum HCV RNA at week 4 of interferon alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis. J Med Virol 1995;46:109-15.
10. Layden TJ, Mika B, Wiley TE. Hepatitis C kinetics: Mathematical modeling of viral response to therapy. Semin Liver Dis 2000;20:173-83.
11. Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alpha. Hepatology 1998;27:1149-56.
12. Zeuzem S. Clinical implications of hepatitis C viral kinetics. J Hepatol 1999;31(suppl 1):61-4.
13. Neumann AU, Zeuzem S. Rapid viral response to treatment with pegylated interferon alpha-2a is strongly predictive of a sustained virological response in patients with chronic hepatitis C. Hepatology 2000;32:318a (abstract).
14. Fried MW, Shiffman ML, Reddy KR, et al. Combination of peginterferon alfa-2a (40kd) plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
15. Ferenci P, Shiffman ML, Fried MW, et al. Early prediction of response to 40KDA peginterferon-alpha-2a plus ribavirin in patients with chronic hepatitis C. Hepatology 2001;34:351A.
16. Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997;26:747-54.
17. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
18. Lunel F, Cresta P, Vitour D, et al. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA and monitor assays. Hepatology 1999;29:528-35.
19. Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus genotypes 1, 2 and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche monitor assay and an in-house limiting dilution method. J Clin Microbiol 1997;35:187-92.
20. Saldanha J, Lelie N, Heath A, for the World Health Organization Collaborative Study Group. Establishment of the first international standard for nucleic acid amplification technology assays for HCV RNA. Vox Sang 1999;76:149-58.
21. Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102.
22. Nolte FS, Fried MW, Shiffman ML, et al. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol 2001;39:4005-12.
23. Ferreira-Gonzalez A, Shiffman ML, Lofland DH, et al. Assessing clinical utility of hepatitis C virus quantitative RT-PCR data. Implications for identification of responders among α-interferon treated patients. Mol Diag 1996;1:109-20.
24. Konnick EQ, Erali M, Ashwood ER, Hillyard DR. Performance characteristics of the COBAS Amplicor hepatitis C virus (HCV) Monitor, version 2.0, international unit assay and the National Genetics Institute HCV Superquant assay. J Clin Microbiol 2002;40:768-73.
25. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
26. Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-43.
27. Urdea MS, Horn T, Fultz TJ, et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acid Symp Ser 1991;24:201-2.
28. Detmer J, Lagier R, Flynn J, et al. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 1996;34:901-7.
29. Busch MP, Wilber JC, Johnson P, et al. Impact of specimen handling and storage on detection of hepatitis C virus RNA. Transfusion 1992;32:420-5.
30. Davis GL, Lau JY, Urdea MS, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: Definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994;19:1337-41.
31. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989;339:237-8.
32. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon-alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
33. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
34. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing peginterferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
35. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.